Search - tctmd.com

Displaying 41 - 60 of 117

Sort: Relevancy | Date

Presentation TVT 2019

Echocardiographic Results of Transcatheter Versus Surgical Aortic Valve Replacement in Low-Risk Patients: The PARTNER 3 Trial

Presenter: Philippe Pibarot

June 14, 2019

News Conference News TVT 2019

Real-world Stroke With TAVR: TVT Registry Insights Rekindle Cerebral Protection Debate

Shelley Wood

June 13, 2019

News Conference News TVT 2019

PCI During or After TAVR No Riskier Than PCI Before Valve Replacement

Michael O'Riordan

June 13, 2019

Presentation TVT 2019

Transcatheter Versus Surgical Aortic Valve Replacement in Low-Risk Patients: A Meta-Analysis of Randomized Controlled Trials

Presenter: Dhaval Kolte

June 13, 2019

Presentation TVT 2019

Comparing the Low-Risk Trials (PARTNER 3 and Medtronic Low-Risk)

Presenter: Martin Leon

June 13, 2019

Presentation TVT 2019

Reactions From the Surgical Community

Presenter: Patrick McCarthy

June 13, 2019

Presentation TVT 2019

Reactions From the Cardiology Community

Presenter: Blase Carabello

June 13, 2019

Presentation TVT 2019

Highlights From the PARTNER 3 Low-Risk Trial

Presenter: Michael Mack

June 13, 2019

Presentation TVT 2019

Highlights From the CoreValve Low-Risk Trial

Presenter: Jeffrey Popma

June 13, 2019

Presentation TVT 2019

The PARTNER 3 Low-Risk Randomized Trial

Presenter: Susheel Kodali

June 13, 2019

Presentation TVT 2019

The Evolut Low-Risk Randomized Trial

Presenter: Steven Yakubov

June 13, 2019

Presentation TVT 2019

Meta-Analysis of 1-Year Outcomes of Transcatheter vs. Surgical Aortic Valve Replacement in Low-Risk Patients With Severe Aortic Stenosis

Presenter: Aaqib H Malik

June 13, 2019

Presentation TVT 2019

Low-Risk Approval: Who Isn’t a Candidate for TAVR?

Presenter: Tsuyoshi Kaneko

June 12, 2019

News Conference News TVT 2017

Merits of Minimalist TAVR: Patient Satisfaction and a Better Bottom Line

Michael O'Riordan

June 20, 2017

News Conference News TVT 2017

Valve Leaflet Thrombosis: Treat It or Leave It Be?

Shelley Wood

June 19, 2017

News Conference News TVT 2017

Lagging Behind: Guidelines Can’t Keep Up With Growing TAVR Evidence Base

Michael O'Riordan

June 17, 2017

News Conference News TVT 2017

Reacting to REPRISE III: Enthusiasm, Explanations, and Caveats for the Lotus Pivotal TAVR Trial

Shelley Wood

June 16, 2017

News Conference News TVT 2017

Volume Underload? More TAVRs Done, the Better the Operator Outcomes, Yet Many Patients Go Untreated

Michael O'Riordan

June 16, 2017

Presentation TVT 2017

SURTAVI Vignette II: Subset Analysis of Patients With STS < 3% (Lower-Risk Patients)

Presenter: David J. Cohen, Jeffrey J. Popma

June 16, 2017

Presentation TVT 2017

A Primer on Surgical Concepts of Structural Valve Deterioration and Guidelines for New Surgical Bioprosthetic Valves Implications for TAVR

Presenter: A. Pieter Kappetein

June 15, 2017

Advertisement

Echocardiographic Results of Transcatheter Versus Surgical Aortic Valve Replacement in Low-Risk Patients: The PARTNER 3 Trial

Real-world Stroke With TAVR: TVT Registry Insights Rekindle Cerebral Protection Debate

PCI During or After TAVR No Riskier Than PCI Before Valve Replacement

Transcatheter Versus Surgical Aortic Valve Replacement in Low-Risk Patients: A Meta-Analysis of Randomized Controlled Trials

Comparing the Low-Risk Trials (PARTNER 3 and Medtronic Low-Risk)

Reactions From the Surgical Community

Reactions From the Cardiology Community

Highlights From the PARTNER 3 Low-Risk Trial

Highlights From the CoreValve Low-Risk Trial

The PARTNER 3 Low-Risk Randomized Trial

The Evolut Low-Risk Randomized Trial

Meta-Analysis of 1-Year Outcomes of Transcatheter vs. Surgical Aortic Valve Replacement in Low-Risk Patients With Severe Aortic Stenosis

Low-Risk Approval: Who Isn’t a Candidate for TAVR?

Merits of Minimalist TAVR: Patient Satisfaction and a Better Bottom Line

Valve Leaflet Thrombosis: Treat It or Leave It Be?

Lagging Behind: Guidelines Can’t Keep Up With Growing TAVR Evidence Base

Reacting to REPRISE III: Enthusiasm, Explanations, and Caveats for the Lotus Pivotal TAVR Trial

Volume Underload? More TAVRs Done, the Better the Operator Outcomes, Yet Many Patients Go Untreated

SURTAVI Vignette II: Subset Analysis of Patients With STS < 3% (Lower-Risk Patients)

A Primer on Surgical Concepts of Structural Valve Deterioration and Guidelines for New Surgical Bioprosthetic Valves Implications for TAVR

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content